Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) have been given an average rating of “Hold” by the five brokerages that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $12.6667.

A number of research firms have weighed in on VRCA. Wall Street Zen lowered shares of Verrica Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. HC Wainwright assumed coverage on Verrica Pharmaceuticals in a research report on Tuesday, May 26th. They issued a “buy” rating and a $12.00 price target for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a report on Wednesday, July 15th. Finally, Lake Street Capital initiated coverage on Verrica Pharmaceuticals in a research report on Thursday, August 27th. They set a “buy” rating and a $9.00 price objective on the stock.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Verrica Pharmaceuticals stock. Renaissance Technologies LLC lifted its position in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) by 22.6% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 32,360 shares of the company’s stock after purchasing an additional 5,960 shares during the quarter. Renaissance Technologies LLC owned about 0.19% of Verrica Pharmaceuticals worth $171,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 42.45% of the company’s stock.

Verrica Pharmaceuticals Price Performance

Verrica Pharmaceuticals stock opened at $4.45 on Monday. The company has a fifty day simple moving average of $5.18 and a 200-day simple moving average of $5.73. The firm has a market capitalization of $76.45 million, a price-to-earnings ratio of -2.66 and a beta of 1.49. The company has a quick ratio of 1.33, a current ratio of 1.45 and a debt-to-equity ratio of 0.18. Verrica Pharmaceuticals has a 52-week low of $3.28 and a 52-week high of $9.82.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc is a dermatology-focused pharmaceutical company developing and commercializing treatments for skin diseases. The company’s work centers on topical therapies designed to address conditions for which patients and healthcare providers have limited treatment options.

Verrica’s lead product, YCANTHE (cantharidin) topical solution, 0.7%, is approved by the U.S. Food and Drug Administration for the treatment of molluscum contagiosum in adults and children ages 2 and older.